Edimer Pharmaceuticals: Working toward improving the health and quality of life of families living with XLHED. Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED). XLHED is a rare, orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. Edimer is led by a team of seasoned biotechnology industry veterans with deep experience in drug development complemented by a strong network of world-class clinical and scientific advisers.

The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load. SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas Skin BioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.

Wuhan Huada Medical Laboratory Co., Ltd., established on 2012-02-17, Business scope includes licensed projects:medical service;Class III medical device business;Import and export;Technology Import and Export;Import and export agency(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Sales of Class II Medical Devices;Non-residential real estate leases;Medical equipment rental;Office equipment rental service;Wholesale of computer software, hardware and auxiliary equipment;Retailing of computer software, hardware and auxiliary equipment;Instrument sales;Experimental analysis instrument sales;Office Equipment Sales;Specialty Chemicals Sales(Free of Hazardous Chemicals);Chemical product sales(No licensed chemical products);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;car used car sales;Daily life services for residents;Sales of Class I Medical Devices(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Apoxis SA develops therapeutics for the treatment of cancer and immunological diseases based on the mechanisms underlying apoptosis or cell death. The company particularly focuses on diseases with unmet medical needs and high commercial potential. It's lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. The product is also being evaluated in a range of cancers in combination with commonly used chemo and radiotherapies in preclinical studies. It's oncology portfolio also includes APO010, a protein therapeutic that was developed using the company’s proprietary multimerization technology. The company is headquartered in Lausanne, Switzerland.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

BGI Shenzhen Co., Ltd. engages in the equity investment and asset management. Its business scope includes research and development and sales of computer hardware and software and peripheral equipment technology; import and export of goods and technology; equity investment; investment in industrial development; and aquatic product farming and sales. The company was founded on August 21, 2008 and is headquartered in Shenzhen, China.

TopoTarget Switzerland has develops oncology and immunology products. The company’s products include APO866, a small molecule therapeutic for the treatment of cancer; and APO010, a protein therapeutic.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Nanjing Qizhen Genetic Engineering Co., Ltd., established on 2018-05-10, Business scope includes gene technology,Biotechnology,medical technology,Technological Development of Agricultural Technology,technical consulting,technology transfer,Technical Services;Biological Products Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Plex Pharmaceuticals, Inc. operates as a biotechnology company which focuses on the discovery of drug-lie small molecules for underserved needs. Its products are used in the treatment of CNS/systemic, oncology, degenerative, CNS disorders and infectious diseases. The company was founded in 2009 and is headquartered in San Diego, CA.